Cover Image
市場調查報告書

中國的胰島素市場

Insulin Market in China 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317341
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
中國的胰島素市場 Insulin Market in China 2014-2018
出版日期: 2014年10月22日 內容資訊: 英文 78 Pages
簡介

中國的胰島素市場,預計從2013年到2018年,以15.57%的年複合成長率擴大。

本報告提供中國的胰島素市場現狀與未來預測、胰島素的各種類的趨勢、市場成長要素與課題、主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 罹患率和得病率

  • 糖尿病

第8章 各種類的市場區隔

  • 基因重組胰島素
  • 現代胰島素

第9章 主要藥物的市場評估

  • Lantus
  • Apidra
  • Insuman
  • Novorapid/Novolog
  • Levemir
  • Novomix/Nologmix
  • Humulin
  • Humalog

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
  • 市場佔有率分析
    • 其他卓越供應商

第18章 主要供應商分析

  • Eli Lilly
  • Novo Nordisk A/S
  • Sanofi
  • Tonghua Dongbao Pharmaceutical

第19章 相關報告

目錄
Product Code: IRTNTR4464

About Insulin

Insulin is a hormone produced in the pancreas. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. Various types of insulin exist depending on how quickly they work, when they peak, and how long they last. In diabetic condition, the pancreas no longer produces adequate insulin or the cells stop responding to the insulin that is produced, leading to rise in blood glucose level.

TechNavio's analysts forecast the Insulin market in China to grow at a CAGR of 15.57 percent over the period 2013-2018.

Covered in this Report

The Insulin market in China can be divided into two segments: Recombinant Insulin and Modern Insulin. This report covers the present scenario and the growth prospects of the Insulin market in China for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products.

TechNavio's report, Insulin Market in China 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Insulin market landscape in China and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Tonghua Dongbao Pharmaceutical

Other Prominent Vendors

  • Abbott Laboratories
  • Bayer Healthcare
  • Biocon
  • Boehringer Ingelheim
  • Gan & Lee Pharmaceutical
  • Glenmark Pharmaceuticals
  • Jiangsu Wanbang Biopharmaceuticals
  • Merck
  • Mylan
  • Pfizer
  • Piramal Healthcare
  • SciGen
  • Shanghai Fosun Pharmaceutical
  • Shenzhen Kexing Biotech
  • Wangbang Pharma Group
  • Wockhardt
  • Yabao Pharmaceutical
  • Zhuhai United Laboratories

Market Driver

  • Increase in Diabetic Population
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Insulin
  • For a full, detailed list, view our report

Market Trend

  • Increase in Strategic Alliances among Vendors
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

    • 07.1.1. Diabetes

08. Market Segmentation by Type

  • 08.1. Recombinant Insulin Market in China
    • 08.1.1. Market Size and Forecast
  • 08.2. Modern Insulin Market in China
    • 08.2.1. Market Size and Forecast

09. Market Assessment of Top Drugs

  • 09.1. Lantus
    • 09.1.1. Sales
  • 09.2. Apidra
    • 09.2.1. Sales
  • 09.3. Insuman
    • 09.3.1. Sales
  • 09.4. Novorapid/Novolog
    • 09.4.1. Sales
  • 09.5. Levemir
    • 09.5.1. Sales
  • 09.6. Novomix/Nologmix
    • 09.6.1. Sales
  • 09.7. Humulin
    • 09.7.1. Sales
  • 09.8. Humalog
    • 09.8.1. Sales

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
  • 17.2. Market Share Analysis 2013
    • 17.2.1. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Eli Lilly
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation by Revenue 2013
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Developments
    • 18.1.8. SWOT Analysis
  • 18.2. Novo Nordisk A/S
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Strategy
    • 18.2.5. Revenue Segmentation by Business
    • 18.2.6. Revenue Comparison by Business Segments 2012 and 2013
    • 18.2.7. Sales by Geography
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
  • 18.3. Sanofi
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Geographical Segmentation by Revenue 2013
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis
  • 18.4. Tonghua Dongbao Pharmaceutical
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2013
    • 18.4.4. Business Segmentation by Revenue 2012 and 2013
    • 18.4.5. Geographical Segmentation by Revenue 2013
    • 18.4.6. Recent Developments
    • 18.4.7. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Insulin Market in China 2013-2018 (US$ billion)
  • Exhibit 3: Insulin Market in China Market Segmentation by Type
  • Exhibit 4: Insulin Market in China Market Segmentation by Type 2013
  • Exhibit 5: Modern Insulin Segmentation by Volume in China 2013
  • Exhibit 6: Onset and Duration of Recombinant Insulin
  • Exhibit 7: Recombinant Insulin Market in China 2013-2018 (US$ billion)
  • Exhibit 8: Modern Insulin Market in China 2013-2018 (US$ billion)
  • Exhibit 9: Sanofi's Lantus Revenue 2010-2013 (US$ million)
  • Exhibit 10: Sanofi's Apidra Revenue 2010-2012 (US$ million)
  • Exhibit 11: Sanofi's Insuman Revenue 2010-2012 (US$ million)
  • Exhibit 12: Novo Nordisk's Novorapid/Novolog Revenue 2010-2013 (US$ million)
  • Exhibit 13: Novo Nordisk's Levemir Revenue 2010-2013 (US$ million)
  • Exhibit 14: Novo Nordisk's Novomix/Nologmix Revenue 2010-2013 (US$ million)
  • Exhibit 15: Eli Lilly's Humulin Revenue 2011-2013 (US$ million)
  • Exhibit 16: Eli Lilly's Humalog Revenue 2011-2013 (US$ million)
  • Exhibit 17: Global Prevalence of Diabetes 2013
  • Exhibit 18: No. of People with Diabetes according to IDF 2030
  • Exhibit 19: Increase in Diabetic Population in China in million
  • Exhibit 20: Insulin Market in China Market Share Analysis 2013
  • Exhibit 21: Insulin Market in China Market Share Analysis by Volume 2013
  • Exhibit 22: Revenue Share of Novo Nordisk's Insulin Products (in Percent)
  • Exhibit 23: Novo Nordisk's Insulin Products Revenue Segmentation by Geography (in Percentage)
  • Exhibit 24: Geography Wise Revenue of Novo Nordisk's Insulin Products (US$ million)
  • Exhibit 25: Revenue of Novo Nordisk's Insulin Products in China (US$ million)
  • Exhibit 26: Sanofi's Insulin Products Revenue Segmentation by Geography (in Percentage)
  • Exhibit 27: Eli Lilly's Insulin Products Revenue Segmentation by Geography (in Percentage)
  • Exhibit 28: Geography Wise Revenue of Eli Lilly's Insulin Products (US$ million)
  • Exhibit 29: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 30: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 31: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 32: Business Segments of Novo Nordisk A/S 2013
  • Exhibit 33: Novo Nordisk A/S: Business Segmentation 2013
  • Exhibit 34: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ million)
  • Exhibit 35: Novo Nordisk A/S: Sales by Geography 2013
  • Exhibit 36: Sanofi: Business Segmentation by Revenue 2013
  • Exhibit 37: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 38: Sanofi: Geographical Segmentation by Revenue 2013
  • Exhibit 39: Tonghua Dongbao Pharmaceutical: Business Segmentation by Revenue 2013
  • Exhibit 40: Tonghua Dongbao Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 41: Tonghua Dongbao Pharmaceutical: Geographical Segmentation by Revenue 2013
Back to Top